Synapse - Works

Results (2146)

Identification of neoantigens from non-primary tumor tissue in patients with recurrent ovarian cancer by sequencing and subsequent HLA ligand mass spectrometry

Meeting Abstract

O'Cearbhaill, R.; Klatt, M.; Mun, S. S.; Korontsvit, T.; Socci, N.; Guzman, S.; Mattar, M.; Zivanovic, O.; Dao, T.
International Journal of Gynecological Cancer (2019)

Fulltext@MSK | Save

Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: Final results

Meeting Abstract

Grisham, R.; Giri, D.; Henson, M.; Iasonos, A.; Zhou, Q.; McDonnell, A.; Girshman, J.; O'Cearbhaill, R.; Zamarin, D.; Aghajanian, C.
International Journal of Gynecological Cancer (2019)

Fulltext@MSK | Save

Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma

Meeting Abstract

Basaran, D.; Bruce, S.; Aviki, E.; Mueller, J.; Broach, V.; Cadoo, K.; Soslow, R.; Alektiar, K.; Abu-Rustum, N.; Leitao, M.
International Journal of Gynecological Cancer (2019)

Fulltext@MSK | Save

MILO/ENGOT-ov11: Phase-3 study of binimetinib versus physician's choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

Meeting Abstract

Grisham, R.; Monk, B. J.; Banerjee, S.; Coleman, R. L.; Oza, A. M.; Oehler, M. K.; Kalbacher, E.; Mirza Raza, M.; del Campo, J. M.; Marth, C.; more...
International Journal of Gynecological Cancer (2019)

Fulltext@MSK | Save

Exploratory analysis of postprogression and patient-centered outcomes in ARIEL3: A phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma

Meeting Abstract

Coleman, R.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
International Journal of Gynecological Cancer (2019)

Fulltext@MSK | Save

Genomic profiling of recurrent "ultra-low risk" endometrial cancer

Meeting Abstract

Stasenko, M.; Feit, N.; Lee, S.; Selenica, P.; Soslow, R. A.; Cadoo, K. A.; Alektiar, K.; Leitao, M. M. Jr; Gardner, G.; Abu-Rustum, N. R.; more...
International Journal of Gynecological Cancer (2019)

Fulltext@MSK | Save

Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M.; Shaffer, D.; Hseih, J. J.; Cohn, A. L.; Di Simone, C.; Marin, A. P.; Rasco, D.; more...
Asia-Pacific Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Meeting Abstract

Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K.; Ben-Baruch, N.; Werner, T. L.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)

Meeting Abstract

González Martín, A.; Pothuri, B.; Vergote, I. B.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Meeting Abstract

Tolaney, S. M.; Wardley, A. M.; Zambelli, S.; Hilton, J.; Troso-Sandoval, T.; Ricci, F.; Im, S. A.; Kim, S. B.; Johnston, S. R. D.; Chan, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save